Article By:
Kate Hayden
Thursday, October 27, 2022 12:18 PM EDT
BriaCell's lead candidate is Bria-IMT, a whole-cell cancer immunotherapy, combined with Incyte’s retifanlimab, for advanced breast cancer. We asked BriaCell’s CEO, William Williams, about the rationale for the combination.